Concert Pharmaceuticals News Releases https://ir.concertpharma.com/ Concert Pharmaceuticals News Releases en Concert Pharmaceuticals Announces Initiation of New Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata https://ir.concertpharma.com/news-releases/news-release-details/concert-pharmaceuticals-announces-initiation-new-open-label LEXINGTON, Mass. --(BUSINESS WIRE)--May 16, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated a second open label clinical trial to evaluate once-daily compared to twice-daily oral dosing of CTP-543 in patients with alopecia areata. Thu, 16 May 2019 07:00:00 -0400 Concert Pharmaceuticals News Releases 10831 Concert Pharmaceuticals to Present at Upcoming Investor Conferences https://ir.concertpharma.com/news-releases/news-release-details/concert-pharmaceuticals-present-upcoming-investor-conferences-4 LEXINGTON, Mass. --(BUSINESS WIRE)--May 14, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate at the following upcoming investor conferences: The UBS Global Healthcare Conference on May 21, 2019 at 10:00 a.m. Tue, 14 May 2019 07:00:00 -0400 Concert Pharmaceuticals News Releases 10826 Concert Pharmaceuticals Reports First Quarter 2019 Financial Results https://ir.concertpharma.com/news-releases/news-release-details/concert-pharmaceuticals-reports-first-quarter-2019-financial Conference Call Scheduled Today at 8:30 a.m. ET LEXINGTON, Mass. --(BUSINESS WIRE)--May 2, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2019. “The progress we are making to advance our pipeline positions us for a series of significant Thu, 02 May 2019 07:00:00 -0400 Concert Pharmaceuticals News Releases 10801 Concert Pharmaceuticals Names Jesper Høiland to its Board of Directors https://ir.concertpharma.com/news-releases/news-release-details/concert-pharmaceuticals-names-jesper-hoiland-its-board-directors LEXINGTON, Mass. --(BUSINESS WIRE)--Apr. 29, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) announced today that Jesper Høiland has been appointed to its Board of Directors and will serve as a member of its Compensation Committee, effective immediately. Mon, 29 Apr 2019 07:00:00 -0400 Concert Pharmaceuticals News Releases 10781 Concert Pharmaceuticals to Report First Quarter 2019 Financial Results on May 2, 2019 https://ir.concertpharma.com/news-releases/news-release-details/concert-pharmaceuticals-report-first-quarter-2019-financial LEXINGTON, Mass. --(BUSINESS WIRE)--Apr. 25, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its first quarter 2019 financial results on Thursday, May 2, 2019 , before the U.S. financial markets open. The Company will host a conference call and webcast at Thu, 25 Apr 2019 07:00:00 -0400 Concert Pharmaceuticals News Releases 10771 Concert Pharmaceuticals to Present CTP-543 Phase 2 Interim Data in Alopecia Areata at 2019 World Congress for Hair Research Annual Meeting https://ir.concertpharma.com/news-releases/news-release-details/concert-pharmaceuticals-present-ctp-543-phase-2-interim-data LEXINGTON, Mass. --(BUSINESS WIRE)--Apr. 11, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that interim clinical data from its CTP-543 Phase 2 trial in alopecia areata will be presented in a poster presentation and a sponsored lecture at the 11 th Annual World Congress for Thu, 11 Apr 2019 07:00:00 -0400 Concert Pharmaceuticals News Releases 10741 Concert Pharmaceuticals Initiates Phase 1 Multiple-Ascending Dose Trial of CTP-692 as an Adjunctive Treatment for Schizophrenia https://ir.concertpharma.com/news-releases/news-release-details/concert-pharmaceuticals-initiates-phase-1-multiple-ascending-0 LEXINGTON, Mass. --(BUSINESS WIRE)--Apr. 10, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated an additional trial in the Phase 1 program evaluating CTP-692, a novel deuterium-modified form of D-serine being developed as an adjunctive treatment for Wed, 10 Apr 2019 06:30:00 -0400 Concert Pharmaceuticals News Releases 10731 Concert Pharmaceuticals Announces Decision from Patent Trial and Appeal Board in IPR Proceeding https://ir.concertpharma.com/news-releases/news-release-details/concert-pharmaceuticals-announces-decision-patent-trial-and LEXINGTON, Mass. --(BUSINESS WIRE)--Apr. 8, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued a final written decision in connection with the inter partes review (IPR) of U.S. Mon, 08 Apr 2019 14:45:00 -0400 Concert Pharmaceuticals News Releases 10726 Concert Pharmaceuticals to Present at Upcoming Oppenheimer Healthcare Conference https://ir.concertpharma.com/news-releases/news-release-details/concert-pharmaceuticals-present-upcoming-oppenheimer-healthcare LEXINGTON, Mass. --(BUSINESS WIRE)--Mar. 12, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the Oppenheimer 29 th Annual Healthcare Conference on March 19, 2019 at 1:00 p.m. ET in New York, NY . Tue, 12 Mar 2019 07:00:00 -0400 Concert Pharmaceuticals News Releases 10651 Concert Pharmaceuticals Announces Initiation of Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata https://ir.concertpharma.com/news-releases/news-release-details/concert-pharmaceuticals-announces-initiation-open-label-trial LEXINGTON, Mass. --(BUSINESS WIRE)--Mar. 6, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated an open label clinical trial to evaluate once-daily compared to twice-daily oral dosing of CTP-543 in patients with alopecia areata. Wed, 06 Mar 2019 07:00:00 -0500 Concert Pharmaceuticals News Releases 10646